December 04, 2017, GOSSELIES, Belgium—Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed. [Read more…]
Cynata Therapeutics Releases Investor Presentation Featuring Operational Progress
Melbourne, Australia; 15 November 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to release a new investor presentation to be presented at a series of upcoming institutional investor meetings.
Paul Wotton (Cynata Chairman) and Ross Macdonald (Cynata CEO) will be meeting with a series of new and existing institutional investors prior to the upcoming AGM on November 17.
Cynata Therapeutics provides investors with excellent exposure to a rapidly growing regenerative medicine and stem cell sector via its patented CymerusTM technology, a platform able to manufacture mesenchymal stem cells (MSCs) at a commercial scale. The new investor presentation highlights Cynata Therapeutics’ compelling investment case and provides information about the Company’s progress. [Read more…]
Enrollment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical Trial
MELBOURNE, Australia, Nov. 15, 2017Â — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001. [Read more…]
Top 10 Most Important iPS Cell Advancesof All Time
In 2006, Shinya Yamanaka and Kazutoshi Takahashi reported the Nobel Prize winning discovery of induced pluripotent stem cells (iPSCs) in Cell, forever changing the landscape of stem cell research.  In the 10 years that have since passed, iPSC technology has advanced the fields of drug discovery, toxicology, disease modelling, and cellular medicine.
To celebrate and honor these achievements, this article highlights the the most epic iPSC advances of all time. [Read more…]
Plasticell and GSK Collaborate to Produce Hematopoietic Cells from iPSCs
October 17th, 2017 – Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research. [Read more…]
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 79
- Next Page »